Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

164 research * retroviral

12th World AIDS Conference

Keyword

Abstract--

SKeyword

Abstract

evention and to identify gaps/Gathering the evidence to i 43524
g priorities for HIV AIDS in countries with limited resource 43534
informed consent" for in a country with marked linguisti 44128
nt)/Ethics in HIV/AIDS in Kenya: The cases of Immunex 474*/44140
s regarding HIV related which involves human subjects/ 44162
IDS: Vulnerable survey subjects/People with AIDS: Vuln 44172
rs to community-based /Politics and practice: Overcomin 44235
d on the street"? Taking back to young homeless people/ 44260
/AIDS surveillance and /Involving aboriginal communitie 44269
ating community-based in AIDS agency programming: A 44293
eatment/Experimental on traditional Chinese medicine: 60048
n HIV/AIDS education,, policy and treatments among m 60351
m/Innovative formative using the WHO narrative researc 60705
counselling at an AIDS centre in Uganda/Helpline telep 60956
n/Researchers and the researched: Partnership for HIV/AIDS pre 14307
Researchers as well as: PLWH/A involvement in eval 60536
I youth/Evaluation of a researcher-community collaboration: Th 13418
r HIV/AIDS prevention/ Researchers and the researched: Partner 14307
nt in evaluation studies/ as well as researched: PLW 60536
abase for providers and researchers /Development of an HIV inter 43242
s a safe sex strategy: Researching something that isn't there/A 14313
odological issues when researching hard to reach groups-working 60832
bination/Prevalence of resistance-associated genotypic mutatio 32301
ANRS 069 pilot study)/ Resistance related mutations in HIV-1 pol 32302
of mutations that confer resistance to RT inhibitors among drug nai 11168
monkeys/Natural host to SIV-induced AIDS: Complex 11217
n/Mutations conferring to protease inhibitors in naive p 12201
NA responses and DLV during combination therapy wit 12206
V-1 activity of and HIV-1 profiles against JE-2147 (KNI- 12270
olecular flexibility for the of HIV-1 protease inhibitors/Im 12277
gimens and associated mutations/Viral load reduction 12342
nti-HIV interactions and profile of the nonnucleoside RT 12366
rs/Prevalence of HIV-1 mutations in a US military coho 13215
gos, Nigeria/Initial drug tuberculosis amongst HIV sero 13255
-5 genotype may confer to mother-to-child HIV-1 trans 11*/21107
is and high rate of drug in an HIV epicenter in northern 452*/22131
mission analysis of drug to M. tuberculosis in a HIV pop 22144
V) retinitis/Ganciclovir in a prospective cohort of HIV-i 22247
ty, and preliminary viral /Co-administration of indinavir 22352
oup and the role of viral in treatment failure/Long-term 22353
for indinavir or ritonavir /Ritonavir, saquinavir, and nevi 22356
s a tool of control and in the organisation of HIV/AIDS 24162
ergence of fluconazole among vaginal candida albican 31216
ents/Anabolic steroids, exercise and protein suppleme 32185
-ocular device/Clinical to ganciclovir in patients with C 32235
rv cvtokines and insulin in HIV infection/Pro-inflammat 32276

ixtures of wild type and point mutations against antiretr 42198
ourg 1992-1997)/Drug mutations in HIV-1 strains from 42199
oxandrolone (OX) plus exercise (RE) on Unitrogen Bal 42335
dults using progressive training/Feasibility of increasin 42357
otide diversity and drug of HIV-1 in saliva and blood/C 60171
+ cells/Broad spectrum to HIV-1 strains by antisense s 60375
Analysis of the HIV RT profile of patients receiving AZ 60854
ces?/Antiretroviral drug detection by LiPA HIV1-RT: A 60968
Injecting Drug Use and Resistant M.tb, Bangkok, Thailand/HIV In 616*/13264

ure/Isolation of MIP-la- resistant
ction with a zidovudinea/Salvage of multi-drug
e of HIV infection/Drug
HIV patients/Multidrugs
ence of co-trimoxazole
treatment of multi drug
e) in patients (pts) with
r HIV-infected patients
gA in a cohort of HIV-1
V retinitis/Incidence of
on of protease inhibitor
aracterization of HIV-1

macrophage-tropic HIV-1 select
strain/CD4 and CD8 response w
HIV infection with d4T/3TC/hydr
pulmonary tuberculosis in a coho
TB (MRTB): Study of an outbrea
strains in community acquired ba
tuberculosis (MDR-TB) in HIV po
human immunodeficiency virus-r
to conventional triple therapy/Fa
Kenyan prostitutes/HIV-1 specifi
cytomegalovirus (CMV) in patien
HIV-1 to a recently infected antir
to modified cyclodextrin sulfate (

oir and differential drug
ction of genotypic drug
orrelation of phenotypic
ent of RT inhibitor (RTI)
notypic and phenotypic
n vivo/Phenotypic HIV
IDS/Antiretroviral drug
genotypic antiretroviral
/Genotypic analysis for
rial (CNAB 3001)/Viral
tinucleoside analogue
notypic and phenotypic
ross resistance/3TC
nation of the multidrug
y for HIV infection/Viral
ion therapy/Genotypic
y/Mutations conferring
wledge of antiretroviral
ive patients/Genotypic
adherence) and drug
oviral efficacy and viral
O)/Increasing antibiotic
tors/Peripheral insulin
he anti-HIV properties,
prevalence of protease
ypic detection of HIV-1
gs of HIV-1 protease/A
o efavirenz/Virologic
uencing for detection of
of nucleoside analogue
pulation/Pattern of drug
rgentina/First study on
easurement of the drug
tations associated with

/Complete HIV pol sequence in 334*/32279
to antiviral nucleoside inhibitor 233*/32282
and clinical efficacy of abacavir 232*/32283
patterns in cerebrospinal fluid ( 563*/32284
to stavudine (d4T) after long-te 32285
in vitro correlates with viral load 231*/32289

/Effects of aerobic and resistive exercise training on body compo
andomized trial (project RESPECT )/Cost of preventing HIV via cou
agement algorithm for respiratory tract infection among a cohort
sessment/An isolation policy for HIV-infected patient
monia (PCP) and acute failure (ARF)/Validation of a
monia (PCP) and acute failure (ARF)/Potential role for
of treatment-emergent tract infections/Clarithromycin
gorithm for treatment of conditions in HIV-1 seropositiv
n viral load during acute infections in HIV infection/Ch
V-1 to preterm twins by syncytial virus infection (RSV)
ng hidden populations/ Respondent-driven sampling: a new appr
e (Viracept~)/Virologic response-plasma drug concentration rela
ment and quality of life/ Restitution of PWA's civil rights: Bearing o
IV disease/The "do not resuscitate " status of hospitalized Africannitis/Rhegmatogenous retinal detachment associated with the ga
er photocoagulation for detachment in cytomegalovirus reti
pidly progressive outer necrosis (PORN)/Varicella zoster v
me of patients with CMV retinitis after adoption of 1996 IAS-USA re
in the outcome of CMV treated with oral ganciclovir (OGC
s with a history of CMV receiving protease inhibitors/Rec
recovery vitritis in CMV patients is immune mediated/Evi
ion of cytomegalovirus (CMV-R) without maintenance the
r the treatment of CMV /Safety profile of low (3.0 mg/ml) a
ytomegalovirus (CMV) /Ganciclovir resistance in a prosp
n of asymptomatic CMV /Routine ophthalmologic screenin
low-up marker of CMV in AIDS patients/The role of cyto
e times a week as CMV maintenance therapy/An open tri
linical practice of CMV treatment with cidofovir in experie
y/Containment of CMV under HAART despite termination
s (CMV) DNA and CMV in AIDS patients/Relationship bet
sting remission of CMV without specific CMV maintenanc
ytomegalovirus (CMV): Experience from the European C
onprogression of CMV in AIDS patients on highly active a
s with cytomegalovirus (CMV-R)/HLA class I antigens an
nt with cytomegalovirus /Extensive optic disc neovasculari
s being treated for CMV /Incidence of resistant cytomegal
vir in patients with CMV and implantation of the ganciclovir
after treatment for CMV (CMVR) with ganciclovir implants
nts with AIDS and CMV /Rhegmatogenous retinal detach
ment in cytomegalovirus /Laser photocoagulation for retina
vir in patients with CMV (CMVR)/Prolonged dosing sched
d HIV viral load on CMV treated with an implant/Significan
ent of cytomegalovirus (CMV-R) in a day care health cent
f CMV antigenemia for versus visceral disease in patients
atment options for CMV in Swiss AIDS patients/Pharmaco
se in patients with CMV /Protease inhibitor therapy is asso
nce of cytomegalovirus in the age of HAART/Community
ting AIDS-related CMV after long-term treatment with gan
res in cytomegalovirus and AIDS/Responsiveness and in
ents/Evolution of CMV in a population of AIDS patients/E
oil filled eyes and CMV /Implantation of ganciclovir device
DS/Urinary excretion of retinol, a-tocopherol and malondialdehyd
al treatment ZDV-DDC ( Retrovir-Hivid ) in adult HIV(+)/AIDS naive
with Rescriptor (DLV) + Retrovir (ZDV) + Epivir (3TC)/lnterim anal
linical features of acute retroviral syndrome in La Plata, Argentina
ay in patients receiving therapy/Cell fusion infectivity as
cal approach to human and syphilis infection among Ma
s/A qualitative study on therapy: Drug compliance in IVD

11110
12184
288*/12205
13254
615*/13274
22117
22125
22297
22375
329*/31101
32233
32288
41198
42328
33263
12407
22137
22188
22436
31205
31208
42161
60597
43420
12304
44262
60287
32237
32238
32246
12158
12347
16*/22239
15*/22240
22244
22245
22247
22249
22251
22254
22256
22260
22265
22268
22270
22271
22272
22273
32233
32235
32236
32237
32238
32239
32243
32244
60191
60374
60405
60550
60659
60713
60782
60786
32187
60235
129*/12219
12202
22407
23561
32361

testing to support the clinical ca
testing (GART) in primary care
testing (GART) as a clinical too
and viral load response to abac
mutation Q151M and the AZT r
in HIV-infected children under
is associated with better HIV su
mutation Q151M/L and the AZ
in a randomised trial comparin
patterns in HIV-infected naive
to zidovudine diminish the virol
translate into improved prescri
in treatment-naive patients/Ge: A model for cross-cultural trea
where no CD4 or RNA monitori
in gonococci in the WHO West
leading to impaired glucose tol
profile and safety of dOTC (2'-d
mutations in therapy-naive HIV
to lamivudine (3TC) and nevira

32290
32291
32292
32293
32296
32298
32299
32300
32303
32304
32306
32307
32313
32363
33167
84*/33231
179*/41177
41196
41208
41209

surmountable HIV protease in 555*/41212
to efavirenz/Virologic 41213
mutations in HIV-1 RT/Line Pr 41219
in a HIV-infected paediatric co 41220
in HIV population/Pattern of dr 41221
profile in a group of drug naive 41227
/Evaluation of the chemothera 42179
to AZT and 3TC after combinati 42197